Cancer Treatment Startup Based on U Research Wins Tekne Award
A startup company that develops next-generation cancer treatments based on University of Minnesota research has been awarded for its innovative therapies.
GeneSegues Therapeutics received the Minnesota High Tech Association’s Tekne Award Wednesday night in the category of Health Care — Small and Growing. Tekne Awards recognize innovation across Minnesota in industries ranging from advanced manufacturing, health care and agricultural technology.
GeneSegues develops microscopic capsules that serve as a vessel to transport gene therapies through the body that help stop the spread of cancer. The capsules are smaller than conventional nanoparticles, allowing them to slip past the human body’s biological barriers and attack cancerous cells more precisely, while leaving healthy cells unharmed.
The company grew out of research done by U of M post-doc Gretchen Unger, Ph.D., in the early 2000s. Unger is currently chief scientific officer with the company. The company’s CEO is Laura Brod, who is also an at-large member of the University’s Board of Regents.